Celularity Inks U.S. Manufacturing Deal for Dezawa MuseCell Platform, Sees $300M Potential
CELU sits 57% above its 52-week low of $0.56.
Summary
Celularity will establish U.S. production of Dezawa MuseCells at its Florham Park, NJ facility under a new collaboration with MuseCell Innovations. The deal covers DMC manufacturing plus derived products like exosomes and secretome. MCI projects the expanded relationship could exceed $300 million in aggregate purchases over five years and create 200+ jobs. This is a significant commercial opportunity for a company with a $25M market cap and recent delisting notices. However, the $300M figure is a non-binding projection, not a committed order. The collaboration leverages Celularity's existing cGMP infrastructure and could provide much-needed revenue diversification.
At the time of this announcement, CELU was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.5M. The 52-week trading range was $0.56 to $4.01. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.